University of North Carolina at Chapel Hill School of Medicine

Medications

Trial results of new drug for generalized myasthenia gravis

Argenx, a Belgium pharmaceutical company, recently announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living ...

Medical research

Is elevated level of lung protein an early predictor for COPD?

Airway mucus consists of various proteins such as long mucins MUC5AC and MUC5B, both of which contribute greatly to the proper gel-like consistency of this most essential bodily fluid. UNC School of Medicine researchers led ...

HIV & AIDS

Study examines incarceration among women at risk for HIV

Nearly half (46.7%) of women in the U.S. at risk for HIV have been incarcerated, according to a new study. The study is published in the peer-reviewed Journal of Women's Health. Click here to read the article now.

page 6 from 31